Venus Concept Announces Regulatory Approval for Venus Bliss MAX in Canada
29 Julio 2024 - 6:30AM
Venus Concept Inc. (“Venus Concept” or the
“Company”) (NASDAQ: VERO), a global medical aesthetic
technology leader, today announced that it has received a medical
device license issued by Health Canada to market the Venus Bliss
MAX system in Canada. The Venus Bliss MAX was first available in
the United States in early 2022 and subsequently offered in
approved jurisdictions around the world.
The Venus Bliss MAX is a 3-in-1 body shaping solution featuring
three of Venus Concept’s market leading technologies in one
complete platform, including diode laser for Fat Reduction
treatments, our proprietary (MP)2 applicator that combines
Multi-Polar Radio Frequency with Pulsed Electro Magnetic Fields and
advanced VariPulse™ technology for Cellulite Reduction and Skin
treatments, and the Company’s FlexMax EMS applicators for Muscle
Toning and Conditioning.
“Venus continues to expand the availability of our flagship body
platform, the Venus Bliss MAX, with our entry into Canada,
providing our customers a comprehensive solution to deliver
multiple advanced non-invasive body treatments in one system,” said
Dr. Hemanth Varghese, President and Chief Operating Officer of
Venus Concept. “Clinicians and aesthetic practices of all
experiences and size in the Canadian market will benefit from this
unique combination of proprietary technologies, further elevating
the results they can deliver to the evolving aesthetic
marketplace.”
Cautionary Statement Regarding Forward-Looking
Statements
This communication contains “forward-looking statements” within
the meaning of Section 27A of the Securities Act of 1933, as
amended and Section 21E of the Securities Exchange Act of 1934, as
amended. Any statements contained herein that are not of historical
facts may be deemed to be forward-looking statements. In some
cases, you can identify these statements by words such as
“anticipates,” “believes,” “plans,” “expects,” “projects,”
“future,” “intends,” “may,” “should,” “could,” “estimates,”
“predicts,” “potential,” and other similar expressions that are
predictions of or indicate future events and future trends. These
forward-looking statements are based on current expectations,
estimates, and projections about our business, and the industry in
which the Company operates and management's beliefs and assumptions
and are not guarantees of future performance or developments and
involve known and unknown risks, uncertainties, and other factors
that are in some cases beyond our control. As a result, any or all
of our forward-looking statements in this communication may turn
out to be inaccurate. Factors that could materially affect our
business operations and financial performance and condition
include, but are not limited to, those risks and uncertainties
described under Part II Item 1A-“Risk Factors” in our Quarterly
Reports on Form 10-Q and Part I Item 1A-“Risk Factors” in our
Annual Report on Form 10-K for the fiscal year ended December 31,
2023. You are urged to consider these factors carefully in
evaluating the forward-looking statements and are cautioned not to
place undue reliance on the forward-looking statements. The
forward-looking statements are based on information available to us
as of the date of this communication. Unless required by law, the
Company does not intend to publicly update or revise any
forward-looking statements to reflect new information or future
events or otherwise.
About Venus Concept
Venus Concept is an innovative global medical aesthetic
technology leader with a broad product portfolio of minimally
invasive and non-invasive medical aesthetic and hair restoration
technologies and reach in over 60 countries and 12 direct markets.
Venus Concept's product portfolio consists of aesthetic device
platforms, including Venus Versa, Venus Versa Pro, Venus Legacy,
Venus Velocity, Venus Viva, Venus Glow, Venus Bliss, Venus Bliss
MAX, Venus Epileve, Venus Viva MD and AI.ME. Venus Concept's hair
restoration systems include NeoGraft® and the ARTAS iX® Robotic
Hair Restoration system. Venus Concept has been backed by leading
healthcare industry growth equity investors including EW Healthcare
Partners (formerly Essex Woodlands), HealthQuest Capital, Longitude
Capital Management, Aperture Venture Partners, and Masters Special
Situations.
Investor Relations Contact:
ICR Westwicke on behalf of Venus Concept:
Mike Piccinino, CFA
VenusConceptIR@westwicke.com
Venus Concept (NASDAQ:VERO)
Gráfica de Acción Histórica
De Nov 2024 a Dic 2024
Venus Concept (NASDAQ:VERO)
Gráfica de Acción Histórica
De Dic 2023 a Dic 2024